| Patient | Mary McLeod Bethune |
|---|---|
| Date of birth | 1953-07-10 |
| Identifiers | MRN HR-ML043-SYN; SSN (made up) 000-43-2195 |
| Document date | 2026-07-27 |
| Author | Viola Harrington-Mbeki, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Asthma review six weeks after an exacerbation. [S]
Mrs. Bethune returns six weeks after the moderate exacerbation that followed a cold, treated at the sick visit with extra budesonide-formoterol, five days of prednisone and a step-up to two maintenance inhalations twice daily. The clinic nurse telephoned her two and seven days later and she was recovering, but she was not seen in person within the week. Since then she has had no night waking and uses the reliever about once a week; she has been to two board meetings in Washington without breathlessness. Her peak flow has been 320 to 345 L/min each morning. She uses the spacer each time and has missed only a few doses. She stopped omeprazole as planned and has had heartburn only once. Home blood pressure averages 126/76. She has had no thoughts of self-harm. [S]
| Element | Detail |
|---|---|
| Exacerbation | Moderate, with a cold, six weeks ago; prednisone for five days; no emergency visit |
| Since then | No night waking; reliever about once a week; peak flow 320 to 345 L/min |
| Travel | Two meetings in Washington without breathlessness |
| System | Result | Finding |
|---|---|---|
| Respiratory | Negative | No night waking or breathlessness on stairs |
| Ears, nose, mouth, and throat | Negative | Nose clear; no hoarseness or thrush |
| Gastrointestinal | Negative | Heartburn once since stopping omeprazole |
| Cardiovascular | Negative | No ankle swelling or chest pain |
| Psychiatric | Negative | Mood good; PHQ-2 0 |
5 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Albuterol 90 mcg/actuation inhaler, two puffs as needed, from an urgent care visit four months ago (used alone, without an inhaled steroid) | Two puffs every 4 hours as needed; she uses it most days | Respiratory tract route | 2025-11-03 to 2026-03-23 | completed | S |
| Prednisone 20 mg oral tablet, two tablets (40 mg) by mouth each morning for five days | 40 mg each morning for five days | Oral route | 2026-06-15 to 2026-06-19 | completed | S |
| Budesonide-formoterol 160/4.5 mcg inhaler as maintenance and reliever (GINA track 1, step 3): one inhalation twice daily and one inhalation as needed for symptoms, no more than 12 inhalations a day | One inhalation twice daily plus one as needed | Respiratory tract route | 2026-03-23 to 2026-06-15 | completed | S |
| Budesonide-formoterol 160/4.5 mcg inhaler with a spacer: two inhalations twice daily and one as needed (stepped up during the exacerbation), no more than 12 inhalations a day | Two inhalations twice daily plus one as needed | Respiratory tract route | 2026-06-15 to 2026-07-27 | completed | S |
| Budesonide-formoterol 160/4.5 mcg inhaler with a spacer: one inhalation twice daily and one as needed, no more than 12 inhalations a day | One inhalation twice daily plus one as needed | Respiratory tract route | 2026-07-27 | active | S |
| Fluticasone propionate 50 mcg/actuation nasal spray, two sprays in each nostril once daily, aimed away from the septum | Two sprays each nostril daily | Nasal route | 2026-03-23 | active | S |
| Sodium chloride 0.65% nasal spray, two sprays in each nostril up to four times daily before the steroid spray | Two sprays each nostril up to four times daily | Nasal route | 2026-03-23 | active | S |
| Amlodipine 5 mg oral tablet, one tablet daily | One tablet daily | Oral route | 2026-03-23 | active | S |
| Atorvastatin 20 mg oral tablet, one tablet daily | One tablet daily | Oral route | 2026-03-23 | active | S |
| Omeprazole 20 mg delayed-release capsule, one capsule daily 30 minutes before breakfast for eight weeks | One capsule daily before breakfast | Oral route | 2026-03-23 to 2026-05-18 | completed | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-07-27 | Body height | 163 | cm | S |
| 2026-07-27 | Body weight | 86.4 | kg | S |
| 2026-07-27 | Body mass index (BMI) [Ratio] | 32.5 | kg/m2 | S |
| 2026-07-27 | Systolic blood pressure | 128 | mm[Hg] | S |
| 2026-07-27 | Diastolic blood pressure | 78 | mm[Hg] | S |
| 2026-07-27 | Heart rate | 72 | /min | S |
| 2026-07-27 | Respiratory rate | 16 | /min | S |
| 2026-07-27 | Body temperature | 36.5 | Cel | S |
| 2026-07-27 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-07-27 | Total score [ACT] | 22 | {score} | S | ||
| 2026-07-27 | FEV1 --pre bronchodilation | 1.72 | L | Lower limit of normal, GLI Global race-neutral equations; predicted 2.03 L | Normal | S |
| 2026-07-27 | FEV1 measured/predicted | 85 | % | GLI Global race-neutral equations | Normal | S |
| 2026-07-27 | FEV1/FVC | 0.73 | {ratio} | >=0.7 | Normal | S |
| 2026-07-27 | Fractional concentration of exhaled nitric oxide | 21 | [ppb] | Above 50 ppb high; 25 to 50 intermediate (ATS) | Normal | S |
| 2026-07-27 | Maximum expiratory gas flow Respiratory system airway by Peak flow meter | 330 | L/min | 80 percent of her personal best of 340 L/min | Normal | S |
| 2026-07-27 | Hemoglobin [Mass/volume] in Blood | 13 | g/dL | 12-15.5 g/dL | Normal | S |
| 2026-07-27 | Leukocytes [#/volume] in Blood by Automated count | 7.1 | 10*3/uL | 4-11 10*3/uL | Normal | S |
| 2026-07-27 | Eosinophils [#/volume] in Blood by Automated count | 0.24 | 10*3/uL | 0-0.5 10*3/uL | Normal | S |
| 2026-07-27 | Platelets [#/volume] in Blood by Automated count | 255 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 2026-07-27 | Potassium [Moles/volume] in Serum or Plasma | 4.3 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-07-27 | Creatinine [Mass/volume] in Serum or Plasma | 0.96 | mg/dL | 0.59-1.04 mg/dL | Normal | S |
| 2026-07-27 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 62 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-07-27 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 0 | {score} | S |
Vital signs recorded on 2026-07-27; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well; weight 86.4 kg; blood pressure 128/78, pulse 72; oxygen saturation 97 percent |
| Respiratory | Clear; no wheeze on forced expiration |
| Mouth | No thrush |
| Extremities | No ankle edema |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Wheeze, cough and breathlessness for four months: waking with cough and tight chest two or three nights a week, breathless on one flight of stairs, relieved by albuterol, worse with colds, dust and strong scents; known asthma for many years but never confirmed by lung function testing and never treated with an inhaled steroid. Asthma, COPD and heart failure to be distinguished: spirometry with bronchodilator response, FeNO and an echocardiogram booked | resolved | confirmed | R06.2 | S — Synthetic presenting problem anchored to her documented chronic asthma. Superseded by the diagnosis at the second visit. |
| Blocked nose, thick postnasal drip and a reduced sense of smell for years, worse in the last year; no nosebleeds; never seen by an ear, nose and throat specialist | resolved | confirmed | R09.81 | S — Synthetic upper-airway symptoms; superseded by the diagnosis of chronic rhinosinusitis after nasal endoscopy. |
| Gastro-esophageal reflux: heartburn and an acid taste two or three evenings a week, worse after late meals and lying down; no trouble swallowing, vomiting, black stools or weight loss | active | confirmed | K21.9 | S — Synthetic comorbidity of asthma; not a claim about her real health. |
| Obesity, class 1 (BMI 33.1); she wants to walk more and to keep up with her work, and agreed to talk about it | active | confirmed | E66.811 | S — Synthetic comorbidity recorded in her words and with her agreement; not a claim about her real weight. |
| Moderate asthma exacerbation triggered by a cold: two days of worsening wheeze and night waking despite eight reliever inhalations a day, peak flow 205 L/min (60 percent of her best), oxygen saturation 94 percent; improved to 275 L/min in clinic; treated without admission; resolved | resolved | confirmed | J45.41 | S — Synthetic exacerbation; not a claim about a real attack. |
| Asthma, confirmed: variable airflow obstruction (FEV1 64 percent predicted, rising 270 mL or 21 percent after bronchodilator, with a normal post-bronchodilator FEV1/FVC of 0.72 and normal DLCO); type 2 inflammation (FeNO 46 ppb, blood eosinophils 0.42 x10^3/uL, total IgE 210, house dust mite sensitization); not COPD and not heart failure. Uncontrolled at diagnosis on albuterol alone | active | confirmed | J45.40 | S — Synthetic modern confirmation linked to her documented chronic asthma. |
| Hypertensive heart disease without heart failure: clinic blood pressure 152/88 and 146/86, home average 144/84; mild concentric left ventricular hypertrophy with grade 1 diastolic dysfunction and a normal ejection fraction (62 percent); BNP 48 pg/mL | active | confirmed | I11.9 | S — Synthetic finding of the modern work-up; not a claim about her real heart. |
| Hyperlipidemia: LDL cholesterol 144 mg/dL; 10-year ASCVD risk above 20 percent with hypertension | active | confirmed | E78.5 | S — Synthetic cardiovascular risk factor. |
| Chronic rhinosinusitis without nasal polyps: years of congestion, postnasal drip and reduced smell, with mucosal swelling and mucus in both middle meatuses and no polyps on nasal endoscopy | active | confirmed | J32.9 | S — Synthetic upper-airway comorbidity of asthma; not a claim about her real health. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Survey | Asthma Control Test, symptoms, night waking and reliever use | Every visit | Completed today | Asthma Control Test 22; reliever about once a week; no night waking |
| Imaging | Spirometry after stabilization and peak flow | Three to six months after starting treatment; peak flow daily after an exacerbation | Completed today | FEV1 1.72 L (85 percent), FEV1/FVC 0.73; peak flow 330 L/min (personal best 340) |
| Imaging | FeNO to monitor response | To monitor anti-inflammatory therapy (NAEPP, conditional) | Completed today | 21 ppb, down from 46 |
| Laboratory | Blood eosinophils for the biologic assessment | At severe asthma assessment; repeat if low | Completed today | 0.24 on inhaled corticosteroid, six weeks after prednisone; white cells 7.1, hemoglobin 13.0, platelets 255 |
| Referral | Biologic assessment | When asthma is severe or uncontrolled despite optimized step 4 to 5 treatment | Not indicated | Not severe asthma: well controlled on medium-dose ICS-formoterol with good technique; to be revisited if control is lost or a second oral corticosteroid course is needed within a year |
| Self-management | Review after an exacerbation | Within one week of any exacerbation (CMID; GINA within one to seven days) | Deferred | Missed: after the exacerbation at the sick visit the nurse telephoned on days 2 and 7, but no in-person review was booked within a week. No harm resulted: she recovered fully and is well controlled today. Corrective action: the action plan and the clinic's exacerbation order set now book a visit within seven days automatically |
| Examination | Inhaler technique with her own inhaler, and adherence | Every visit; before any step-up | Completed today | Correct with the spacer; few missed doses |
| Self-management | Exacerbation history (oral corticosteroid courses, emergency visits, admissions) | Every visit | Completed today | One moderate exacerbation six weeks ago (one prednisone course this year); no emergency visit or admission |
| Self-management | Step-up or step-down assessment (GINA track 1) | Every visit | Completed today | Stepped back down to low-dose maintenance and reliever |
| Self-management | Written asthma action plan | Every visit and after every exacerbation | Completed today | Updated with her personal best of 340 L/min after the exacerbation |
| Self-management | Triggers, exposures and smoking or vaping | Every visit | Completed today | Colds the main trigger; vaccines planned for the autumn |
| Referral | Pulmonary rehabilitation | For persistent breathlessness or deconditioning | Not indicated | No persistent breathlessness; walking daily |
| Examination | Blood pressure in clinic and at home | Every visit; home readings at diagnosis and after changes | Completed today | Clinic 128/78; home average 126/76: at target |
| Laboratory | Potassium and kidney function | Yearly, or after changes | Completed today | Potassium 4.3, creatinine 0.96, eGFR 62 |
| Survey | Depression screen | Yearly and as needed | Completed today | PHQ-2 0 |
Goal progress:
Guideline basis: CMID: Clinical Monitoring Intelligence Database, asthma and hypertension monographs (2026); Global Strategy for Asthma Management and Prevention, 2025 update (2025); 2020 Focused Updates to the Asthma Management Guidelines: A Report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group (2020); 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults (2025); Bhakta NR, et al. Race and Ethnicity in Pulmonary Function Test Interpretation: An Official American Thoracic Society Statement. Am J Respir Crit Care Med 2023;207(8):978-995 (PMID 36973004) (2023)
Follow-up: Asthma and blood pressure review in three months. Annual wellness visit in about two months, with influenza, COVID-19 and RSV vaccines. Follow the updated action plan. Next scheduled visit 2026-09-21: subsequent annual wellness visit. [S]